Pleasanton, California – February 7, 2024 – n6 Tec Inc., a next generation sequencing and molecular biology platform company, announced the completion of a growth
iconPCR enables optimal high-throughput PCR for next generation sequencing and molecular biology applications PLEASANTON, CA – February 6, 2024— n6 Tec has launched the world’s
Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) —
Positions the Company as a new leader in providing solutions that bridge the gap between cellular electrophysiology and advanced analysis techniques DURHAM, NORTH CAROLINA, UNITED
ST. LOUIS, March 15, 2023 /PRNewswire/ — Panome Bio, a metabolomics and proteomics services company that provides biopharma innovators unparalleled access into the biomolecules closest
VENLO, The Netherlands & SAN DIEGO–(BUSINESS WIRE)– QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced it has completed the acquisition of Verogen, a leader in the
Madison, WI USA, January 5, 2023–/BusinessWire/ — Nimble Therapeutics, a biotechnology company leveraging its next-generation peptide discovery platform to identify medicines for challenging-to-drug targets, today
MADISON, WI, USA, December 13, 2022 — Nimble Therapeutics Inc., a leading peptide therapeutics company, today announced they have achieved discovery milestones for two programs
Madison, Wisconsin, November 30th, 2022 – Nimble Therapeutics, an industry-leading peptide therapeutics company, today announced the appointment of Pete Gough, D. Phil. as Chief Scientific
October 24, 2022 | For Immediate Release Former Healthcare Research Analyst and Investment Banker Expands Firm’s Operational Depth and Sector Expertise San Francisco, California (October
San Francisco, June 30, 2022 – Telegraph Hill Partners (THP), a venture capital and growth equity firm dedicated to building life science and healthcare technology
The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced
This website uses cookies and similar technologies to support basic site functionality and help us understand how visitors use the site. We use analytics tools such as Google Analytics, to improve website performance and content.We do not sell personal information or use cookies for targeted advertising.You can accept all cookies, reject non-essential cookies, or adjust your preferences at any time. For more information, please review our Privacy Policy.
Essential cookies and services enable basic functions and are necessary for the proper functioning of the website.
This category includes all cookies, domains, and services that do not fall into the other specified categories or have not been explicitly categorized.
This website uses cookies to enhance your browsing experience and ensure the site functions properly. By continuing to use this site, you acknowledge and accept our use of cookies.
